2022). A limited number of studies has shown that ATG3 was dysregulated in some clinical disorders, including cerebral ischemia/reperfusion injury, gastric and colon cancer (da Silva Lima et al. 2022; Huang et al. 2019; Peng et al. 2021). The findings of these studies offer substantial evidence on the involvement of ATG3 in several pathophysiological processes, such as damage, inflammation, proliferation, invasion, and mitochondrial function (da Silva Lima et al. 2022; Huang et al. 2019; Peng et al. 2021). Here, ATG3 is linked to malignant colon neoplasm.